CN101181069B - Complex nutrition albumen powder for preventing women's osteosporosis after menopause - Google Patents
Complex nutrition albumen powder for preventing women's osteosporosis after menopause Download PDFInfo
- Publication number
- CN101181069B CN101181069B CN200710150586XA CN200710150586A CN101181069B CN 101181069 B CN101181069 B CN 101181069B CN 200710150586X A CN200710150586X A CN 200710150586XA CN 200710150586 A CN200710150586 A CN 200710150586A CN 101181069 B CN101181069 B CN 101181069B
- Authority
- CN
- China
- Prior art keywords
- protein powder
- women
- soybean
- group
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000843 powder Substances 0.000 title claims abstract description 49
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 19
- 230000009245 menopause Effects 0.000 title description 2
- 230000035764 nutrition Effects 0.000 title 1
- 235000018102 proteins Nutrition 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 30
- 244000068988 Glycine max Species 0.000 claims abstract description 30
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 14
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 14
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 14
- 235000021119 whey protein Nutrition 0.000 claims abstract description 14
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 13
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 12
- 239000000787 lecithin Substances 0.000 claims abstract description 12
- 235000010445 lecithin Nutrition 0.000 claims abstract description 12
- 229940067606 lecithin Drugs 0.000 claims abstract description 12
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 11
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims abstract description 11
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000003381 stabilizer Substances 0.000 claims abstract description 5
- 235000003687 soy isoflavones Nutrition 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 abstract description 19
- 235000008696 isoflavones Nutrition 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 150000002515 isoflavone derivatives Chemical class 0.000 abstract description 17
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 abstract description 7
- 235000011086 calcium lactate Nutrition 0.000 abstract description 7
- 229960002401 calcium lactate Drugs 0.000 abstract description 7
- 239000001527 calcium lactate Substances 0.000 abstract description 7
- 239000000047 product Substances 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 4
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract description 3
- 229940116540 protein supplement Drugs 0.000 abstract description 2
- 235000005974 protein supplement Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000005186 women's health Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical group C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 18
- 208000001132 Osteoporosis Diseases 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 229960005069 calcium Drugs 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 108090000573 Osteocalcin Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940001941 soy protein Drugs 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000004067 Osteocalcin Human genes 0.000 description 3
- 102100031475 Osteocalcin Human genes 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000907663 Siproeta stelenes Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- -1 isomaltose oligosaccharides Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003157 protein complementation Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于预防妇女绝经后骨质疏松的复合营养蛋白粉,其组成成分及其重量百分比分别为:大豆蛋白粉55~80%;乳清蛋白粉15~35%;大豆异黄酮0.2~0.8%;低聚糖1~5%;乳酸钙1.2~2.4%;稳定剂0.5~1%;卵磷脂0.5~1.5%。本发明产品食用安全可靠,效果好,无毒副作用,无依赖性,经常食用可保护中年妇女的健康,尤其是可以改善妇女由于雌激素缺乏所引发的健康问题,提高其生命质量和生活质量,可作为妇女经常食用的蛋白质补充产品。The invention relates to a compound nutritional protein powder for preventing women's postmenopausal osteoporosis. The components and weight percentages thereof are: soybean protein powder 55-80%; whey protein powder 15-35%; soybean isoflavones 0.2-0.8%; oligosaccharides 1-5%; calcium lactate 1.2-2.4%; stabilizer 0.5-1%; lecithin 0.5-1.5%. The product of the invention is safe and reliable to eat, has good effect, has no toxic and side effects, and has no dependence. Regular consumption can protect the health of middle-aged women, especially can improve women's health problems caused by estrogen deficiency, and improve their quality of life and quality of life. , can be used as a protein supplement product that women often consume.
Description
技术领域 technical field
本发明涉及一种复合营养蛋白粉,尤其涉及一种用于预防妇女绝经后骨质疏松的复合营养蛋白粉。The invention relates to a compound nutritional protein powder, in particular to a compound nutritional protein powder for preventing postmenopausal osteoporosis in women.
背景技术 Background technique
随着我国老龄人口的增加,骨质疏松症也成为继心血管疾病和癌症之后又一个威胁我们健康的疾病。调查表明,目前我国已经是世界上拥有骨质疏松症患者最多的国家,约有9000万患者,约占总人口的7%。With the increase of our country's aging population, osteoporosis has become another disease that threatens our health after cardiovascular disease and cancer. Investigations show that my country is the country with the largest number of osteoporosis patients in the world at present, with about 90 million patients, accounting for about 7% of the total population.
骨质疏松对绝经后妇女的危害尤为严重。妇女绝经后体内雌激素水平急剧下降,对破骨细胞的抑制减弱,骨溶解加速,骨形成作用变弱,造成骨钙大量丢失,从而引发骨质疏松。在我国,60~69岁老年妇女骨质疏松发生率高达50%~70%,因此,如何预防绝经后骨质疏松、防止骨折的发生是我们需要关注的重要课题。Osteoporosis is particularly harmful to postmenopausal women. After menopause, the level of estrogen in the body of women drops sharply, the inhibition of osteoclasts is weakened, the osteolysis is accelerated, and the bone formation is weakened, resulting in a large loss of bone calcium, which leads to osteoporosis. In my country, the incidence rate of osteoporosis in 60-69-year-old women is as high as 50%-70%. Therefore, how to prevent postmenopausal osteoporosis and prevent fractures is an important topic that we need to pay attention to.
雌激素替代疗法(HRT)是预防绝经后妇女骨质疏松的主要方法,大量的研究表明应用HRT能够很好的预防绝经后的骨质疏松,但HRT在预防骨质疏松的同时会产生其副作用,如乳腺癌、卵巢癌、心血管病和胃肠的不良反应等,以及一些妇女的心理顾虑,不能为所有缺乏雌激素的女性所接受。Estrogen replacement therapy (HRT) is the main method to prevent osteoporosis in postmenopausal women. A large number of studies have shown that the application of HRT can prevent postmenopausal osteoporosis very well, but HRT will produce its side effects while preventing osteoporosis , Such as breast cancer, ovarian cancer, cardiovascular disease and gastrointestinal adverse reactions, as well as some women's psychological concerns, cannot be accepted by all women who lack estrogen.
随着对植物源性雌激素样物质的进一步了解与研究,药学家开始对植物雌激素发生了兴趣。目前,植物雌激素尤其是异黄酮类被宣传为“健康保健产品”。具有雌激素作用的大豆,尤其是大豆中的异黄酮,对绝经后骨质疏松有一定的预防作用。With the further understanding and research on plant-derived estrogen-like substances, pharmacists have become interested in phytoestrogens. At present, phytoestrogens, especially isoflavones, are promoted as "health care products". Soybeans with estrogenic effects, especially the isoflavones in soybeans, have a certain preventive effect on postmenopausal osteoporosis.
发明内容 Contents of the invention
本发明的目的是提供一种能够全面、有效、安全预防妇女绝经后骨质疏松的复合营养蛋白粉,以保护中年妇女的健康,提高生命质量和生活质量。The purpose of the present invention is to provide a compound nutritional protein powder capable of comprehensively, effectively and safely preventing postmenopausal osteoporosis in women, so as to protect the health of middle-aged women and improve the quality of life and quality of life.
本发明采取的技术方案是:The technical scheme that the present invention takes is:
一种预防妇女绝经后骨质疏松的复合营养蛋白粉,其组成成分及其重量百分比分别为:A compound nutritional protein powder for preventing women's postmenopausal osteoporosis, its composition and weight percentage are respectively:
大豆蛋白粉 55~80%Soy protein powder 55~80%
乳清蛋白粉 15~35%Whey protein powder 15~35%
大豆异黄酮 0.2~0.8%Soy Isoflavones 0.2~0.8%
低聚糖 1~5%Oligosaccharides 1~5%
乳酸钙 1.2~2.4%Calcium lactate 1.2~2.4%
稳定剂 0.5~1%Stabilizer 0.5~1%
卵磷脂 0.5~1.5%。Lecithin 0.5-1.5%.
而且,所述的大豆蛋白粉为大豆分离蛋白,其蛋白质含量≥60%。Moreover, the soybean protein powder is soybean protein isolate, and its protein content is more than or equal to 60%.
而且,所述的乳清蛋白粉为乳清浓缩蛋白,其蛋白质含量≥60%。Moreover, the whey protein powder is concentrated whey protein, and its protein content is more than or equal to 60%.
而且,所述的大豆异黄酮中总大豆异黄酮含量≥40%。Moreover, the total soy isoflavone content in the said soy isoflavones is more than or equal to 40%.
而且,所述的大豆异黄酮的含量是以总大豆异黄酮含量计算。Moreover, the content of said soy isoflavones is calculated based on the total soy isoflavones content.
而且,所述的低聚糖为大豆低聚糖或低聚异麦芽糖或低聚果糖或低聚乳糖或低聚半乳糖。Moreover, the oligosaccharides are soybean oligosaccharides or isomaltose oligosaccharides or fructooligosaccharides or lactooligosaccharides or galactooligosaccharides.
而且,所述的稳定剂为黄原胶或卡拉胶,或两者的混合物。Moreover, the stabilizer is xanthan gum or carrageenan, or a mixture of both.
而且,所述的卵磷脂是已均质的卵磷脂。Furthermore, said lecithin is homogenized lecithin.
本发明的优点和积极效果是:Advantage and positive effect of the present invention are:
1.本发明以大豆分离蛋白粉和乳清蛋白粉为主体,利用动植物蛋白互补原理,将大豆蛋白和乳清蛋白按一定比例混合,使其九种必需氨基酸的含量更接近人体所需的氨基酸模式,极易为人体吸收及利用;另外在配方中添加乳化剂卵磷脂和稳定剂黄原胶或/和卡拉胶,使蛋白粉具有良好的稳定性和感官品质。1. The present invention takes soybean protein isolate powder and whey protein powder as the main body, uses the principle of animal and plant protein complementation, mixes soybean protein and whey protein in a certain proportion, and makes the content of the nine essential amino acids closer to what the human body needs. The amino acid mode is easily absorbed and utilized by the human body; in addition, the emulsifier lecithin and the stabilizer xanthan gum or/and carrageenan are added to the formula to make the protein powder have good stability and sensory quality.
2.本发明强化了功能成份大豆异黄酮和促进大豆异黄酮吸收的低聚糖,从而达到预防妇女绝经期骨质疏松的作用。对去卵巢大鼠骨质疏松的预防作用试验表明:强化大豆异黄酮的营养蛋白粉对去卵巢大鼠的骨质疏松有预防作用。2. The present invention strengthens the functional ingredient soybean isoflavones and the oligosaccharides that promote the absorption of soybean isoflavones, thereby achieving the effect of preventing osteoporosis in menopausal women. The preventive effect test on osteoporosis in ovariectomized rats showed that the nutritional protein powder fortified with soybean isoflavones has a preventive effect on osteoporosis in ovariectomized rats.
3.本发明所添加的低聚糖能够调节机体胃肠道正常菌群,产生特殊酶系,不仅能促进内源性雌激素再吸收,提高机体的内源性雌激素水平,同时还可以提高大豆异黄酮的吸收和再吸收,具有提高内源性雌激素水平和补充外源性雌激素样物质的双重作用,因而对于预防绝经后骨质疏松症、绝经期综合症和乳腺癌具有更显著的效果。3. The oligosaccharides added by the present invention can regulate the normal flora of the gastrointestinal tract of the body and produce special enzymes, which can not only promote the reabsorption of endogenous estrogen, improve the level of endogenous estrogen in the body, but also increase the level of endogenous estrogen in the body. The absorption and reabsorption of soy isoflavones have dual effects of increasing endogenous estrogen levels and supplementing exogenous estrogen-like substances, so it has a more significant effect on preventing postmenopausal osteoporosis, menopausal syndrome and breast cancer. Effect.
4.本发明的功能成份大豆异黄酮可以缓解女性更年期综合征的各种不适,改善睡眠;可以预防心脑血管疾病,降低妇女乳腺癌的发生,对防治老年痴呆(阿尔茨海默病)也有一定效用。4. The functional ingredient soy isoflavones of the present invention can alleviate the various discomforts of women's climacteric syndrome, improve sleep; can prevent cardiovascular and cerebrovascular diseases, reduce the occurrence of women's breast cancer, and also have an effect on preventing and treating senile dementia (Alzheimer's disease). Certain utility.
5.本发明的功能成份低聚糖还具有降血脂、降血糖、促进矿物元素的吸收等功效。5. The functional component oligosaccharides of the present invention also have the effects of lowering blood fat, lowering blood sugar, and promoting the absorption of mineral elements.
6.本发明中的乳酸钙是钙源,在大豆异黄酮的存在与作用下,容易被人体吸收。6. Calcium lactate in the present invention is a calcium source, and is easily absorbed by the human body under the presence and action of soybean isoflavones.
7.本发明中的卵磷脂具抗氧化及乳化作用,使蛋白粉更易被人体消化和吸收,且有助于蛋白质混合,不易形成胶块,溶解更快更好。7. The lecithin in the present invention has antioxidant and emulsifying effects, which makes the protein powder easier to be digested and absorbed by the human body, and helps the protein to mix, is not easy to form glue blocks, and dissolves faster and better.
8.本发明产品食用安全可靠,效果好,无毒副作用,无依赖性,可作为妇女经常食用的蛋白质补充产品。8. The product of the present invention is safe and reliable to eat, has good effect, has no toxic and side effects, and has no dependence, and can be used as a protein supplement product that women often eat.
具体实施方式 Detailed ways
下面结合实施例,对本发明进一步说明;下述实施例是说明性的,不是限定性的,不能以下述实施例来限定本发明的保护范围。Below in conjunction with embodiment, the present invention is further described; Following embodiment is illustrative, not limiting, can not limit protection scope of the present invention with following embodiment.
首先需要说明的是:First things first:
大豆蛋白粉为大豆分离蛋白,其蛋白质含量≥60%。Soybean protein powder is soybean protein isolate, and its protein content is ≥60%.
乳清蛋白粉为乳清浓缩蛋白,其蛋白质含量≥60%。Whey protein powder is whey protein concentrate with a protein content ≥ 60%.
大豆异黄酮中总大豆异黄酮含量≥40%,该大豆异黄酮的含量是以总大豆异黄酮含量计算的。The content of total soybean isoflavones in soybean isoflavones is more than or equal to 40%, and the content of soybean isoflavones is calculated based on the content of total soybean isoflavones.
低聚糖可采用大豆低聚糖或低聚异麦芽糖或低聚果糖或低聚乳糖或低聚半乳糖的其中一种。The oligosaccharides can be one of soybean oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, lactooligosaccharides or galactooligosaccharides.
实施例1:(下述各原料百分含量均为重量百分含量)Embodiment 1: (following each raw material percentage composition is weight percent composition)
大豆蛋白粉 75%Soy protein powder 75%
乳清蛋白粉 25%Whey Protein Powder 25%
大豆异黄酮 0.3%Soy Isoflavones 0.3%
大豆低聚糖 3%Soybean oligosaccharides 3%
乳酸钙 2%Calcium Lactate 2%
黄原胶 0.7%Xanthan Gum 0.7%
卵磷脂 1%。Lecithin 1%.
本发明的生产工艺步骤如下:Production technology step of the present invention is as follows:
按上述重量百分数分别称取大豆蛋白粉、乳清蛋白粉、黄原胶、乳酸钙、低聚糖和已均质的卵磷脂混合,根据本申请人申请的专利2006100133037.3“应有沸腾床喷涂卵磷脂造粒技术生产的蛋白粉及其制备方法”所介绍的方法生产复合蛋白粉,收集,加入大豆异黄酮,混匀,灭菌,无菌包装,25g分装、装小包、装大包、装箱。检验、成品入库。Weigh soybean protein powder, whey protein powder, xanthan gum, calcium lactate, oligosaccharides and homogenized lecithin according to the above weight percentages and mix them. Protein powder produced by phospholipid granulation technology and its preparation method" to produce compound protein powder, collect, add soybean isoflavones, mix, sterilize, aseptically package, 25g sub-package, pack small packs, pack large packs, packing. Inspection, finished product storage.
实施例2:(下述各原料百分含量均为重量百分含量)Embodiment 2: (following each raw material percentage composition is weight percent composition)
大豆蛋白粉 80%Soy Protein Powder 80%
乳清蛋白粉 20%Whey Protein Powder 20%
大豆异黄酮 0.5%Soy Isoflavones 0.5%
低聚异麦芽糖 5%Isomaltooligosaccharide 5%
乳酸钙 2%Calcium Lactate 2%
卡拉胶 0.7%Carrageenan 0.7%
卵磷脂 1%。Lecithin 1%.
制备工艺的步骤同实施例1。The steps of the preparation process are the same as in Example 1.
实施例3:(下述各原料百分含量均为重量百分含量)Embodiment 3: (following each raw material percentage composition is weight percent composition)
大豆蛋白粉 70%Soy protein powder 70%
乳清蛋白粉 30%Whey Protein Powder 30%
大豆异黄酮 0.6%Soy Isoflavones 0.6%
低聚果糖 4%Fructo-oligosaccharides 4%
乳酸钙 2%Calcium Lactate 2%
黄原胶 0.7%Xanthan Gum 0.7%
卵磷脂 1%。Lecithin 1%.
制备工艺的步骤同实施例1。The steps of the preparation process are the same as in Example 1.
本发明的动物实验结果如下:Animal experiment result of the present invention is as follows:
经动物实验证实,本发明产品可以明显的预防去卵巢大鼠骨质疏松的发生,其实验步骤及结果如下:It has been confirmed by animal experiments that the product of the present invention can obviously prevent the occurrence of osteoporosis in ovariectomized rats. The experimental steps and results are as follows:
1.动物来源及分组1. Animal source and grouping
50只未交配过的健康雌性SD大鼠,3.5月龄,体重250-280g,大鼠在本实验室适应1周后,按体重随机分为5组,每组10只:50 unmated healthy female SD rats, 3.5 months old, weighing 250-280g, were acclimatized in this laboratory for 1 week, and were randomly divided into 5 groups according to body weight, with 10 rats in each group:
(1).假性手术对照组(Sham):假手术,即进行卵巢切除术相同的手术过程,但不摘除卵巢,只切除一小块脂肪,饲料蛋白质来源为酪蛋白;(1). Sham operation control group (Sham): Sham operation, that is, the same operation process as ovariectomy, but without removing the ovary, only a small piece of fat was removed, and the protein source of feed was casein;
(2).去卵巢对照组(Ovx):去卵巢,饲料蛋白质来源为酪蛋白;(2). Ovariectomized control group (Ovx): ovariectomized, feed protein source is casein;
(3).未强化大豆异黄酮组(0-SI):去卵巢,饲料蛋白质来源为未强化大豆异黄酮的普通营养蛋白粉;(3). Unenhanced soybean isoflavones group (0-SI): ovariectomized, and the source of dietary protein is ordinary nutritional protein powder without fortified soybean isoflavones;
(4).中剂量大豆异黄酮组(M-SI):去卵巢,饲料蛋白质来源为强化大豆异黄酮的营养蛋白粉,其添加量为350mg/100g蛋白粉;(4). Medium-dose soybean isoflavone group (M-SI): ovariectomized, feed protein source is nutritional protein powder fortified with soybean isoflavone, and its addition amount is 350mg/100g protein powder;
(5).高剂量大豆异黄酮组(H-SI):去卵巢,饲料蛋白质来源为强化大豆异黄酮的营养蛋白粉,其添加量为760mg/100g蛋白粉。(5). High-dose soybean isoflavone group (H-SI): the ovariectomized, feed protein source is nutritional protein powder fortified with soybean isoflavone, and the added amount is 760mg/100g protein powder.
各组动物基础饲料相同,饲养环境温度为20-24℃,湿度40-60%,12小时光照交替,自由饮水和进食。手术后大鼠恢复1周进入正式实验期,每天观察动物饮食情况,每周称体重一次,每3天记录饲料的消耗量,同时结算各组每天的摄食量。饲养3个月后,禁食24小时,处死大鼠,采集所需样本进行功能评价。Animals in each group had the same basal feed, the temperature of the feeding environment was 20-24°C, the humidity was 40-60%, the light was alternated for 12 hours, and water and food were free to drink. After the operation, the rats recovered for 1 week and entered the formal experiment period. The diet of the animals was observed every day, the body weight was weighed once a week, the feed consumption was recorded every 3 days, and the daily food intake of each group was calculated at the same time. After feeding for 3 months, the rats were fasted for 24 hours, and the rats were sacrificed, and the required samples were collected for functional evaluation.
2.测定指标及方法2. Measuring indicators and methods
用双能量X射线骨密度(BMD)仪测定大鼠股骨骨密度;利用原子吸收法测定骨钙;骨磷采用孔雀绿-磷钼酸比色法测定;比色法测定血清碱性磷酸酶活性;竞争性放射免疫法测定血清骨钙素含量。The femur bone mineral density of rats was measured by dual-energy X-ray bone density (BMD) instrument; bone calcium was measured by atomic absorption method; bone phosphorus was measured by malachite green-phosphomolybdic acid colorimetric method; serum alkaline phosphatase activity was measured by colorimetric method ; Determination of serum osteocalcin content by competitive radioimmunoassay.
3.统计学处理3. Statistical processing
所有数据用SPSS统计软件进行分析处理,结果以均数标准差表示x±S表示,差异显著性以P<0.05和P<0.01表示。All data were analyzed and processed with SPSS statistical software, and the results were expressed as mean and standard deviation x±S, and the significance of the difference was expressed as P<0.05 and P<0.01.
4.营养蛋白粉对去卵巢大鼠体重的影响4. Effect of nutritional protein powder on body weight of ovariectomized rats
各组大鼠一般情况和术后伤口愈合良好,无感染。五组大鼠体重均增加,在实验第15天5组间体重出现统计学差异,去卵巢对照组和未强化异黄酮组体重明显高于假性手术组和异黄酮组,差异有统计学意义(P<0.05,表1);至实验期末去卵巢对照组和未强化异黄酮组体重持续高于假性手术组,差异有统计学意义(P<0.01),而强化不同剂量异黄酮组和假性对照组相比体重没有显著增高。说明强化大豆异黄酮的营养蛋白粉可以预防去卵巢大鼠由于雌激素缺乏而引发的肥胖。The general condition of the rats in each group and postoperative wound healing were good without infection. The weight of the five groups of rats all increased, and there was a statistical difference in the weight of the five groups on the 15th day of the experiment. The weight of the ovariectomized control group and the non-enhanced isoflavone group was significantly higher than that of the sham operation group and the isoflavone group, and the difference was statistically significant (P<0.05, Table 1); until the end of the experiment period, the weight of the ovariectomized control group and the non-enhanced isoflavone group was continuously higher than that of the sham operation group, and the difference was statistically significant (P<0.01), while the body weight of the fortified different doses of isoflavone group and the Compared with the sham control group, the body weight did not increase significantly. It shows that nutritional protein powder fortified with soy isoflavones can prevent obesity caused by estrogen deficiency in ovariectomized rats.
表1营养蛋白粉对去卵巢大鼠体重的影响(x±S)Table 1 The impact of nutritional protein powder on the body weight of ovariectomized rats (x ± S)
注:a与假性手术组相比P<0.05,b与假性子术组相比P<0.01Note: a P<0.05 compared with the sham operation group, b P<0.01 compared with the sham operation group
5.营养蛋白粉对去卵巢大鼠骨密度、骨钙和骨磷的影响5. Effect of nutritional protein powder on bone mineral density, bone calcium and bone phosphorus in ovariectomized rats
从表2可以看出,与假性手术组相比去卵巢对照组大鼠骨密度显著下降(P<0.01),下降12.9%,给予强化不同剂量大豆异黄酮的蛋白粉后,骨密度都有显著提高(P<0.05和P<0.01),与去卵巢对照组相比M-SI组和H-SI组分别提高5.9%和12.1%,与未强化大豆异黄酮组相比M-SI组和H-SI组分别提高2.7%和9.9%。As can be seen from Table 2, compared with the sham operation group, the bone mineral density of rats in the ovariectomized control group decreased significantly (P<0.01), down 12.9%. Significantly increased (P<0.05 and P<0.01), compared with the ovariectomized control group, the M-SI group and the H-SI group increased by 5.9% and 12.1%, respectively, and compared with the unenhanced soybean isoflavone group, the M-SI group and the The H-SI group improved by 2.7% and 9.9%, respectively.
与假性手术组相比去卵巢对照组骨钙和骨磷显著下降(P<0.01),分别下降3.8%和12.7%,而给予强化异黄酮的蛋白粉后骨钙和骨磷都显著提高(P<0.01),与去卵巢对照组相比不同剂量异黄酮组骨钙分别提高4.2%和4.8%,骨磷分别提高13.1%和12.7%,与未强化大豆异黄酮组相比不同剂量异黄酮组骨钙含量分别提高4.6%和5.2%,骨磷含量分别提高11.5%和11.8%。Compared with the sham operation group, bone calcium and bone phosphorus in the ovariectomized control group decreased significantly (P<0.01), decreased by 3.8% and 12.7% respectively, while bone calcium and bone phosphorus all increased significantly after giving protein powder fortified with isoflavones ( P<0.01), compared with the ovariectomized control group, bone calcium in different doses of isoflavone groups increased by 4.2% and 4.8%, bone phosphorus increased by 13.1% and 12.7%, respectively, and different doses of isoflavones compared with non-enhanced soybean isoflavone group The bone calcium content of the two groups increased by 4.6% and 5.2%, respectively, and the bone phosphorus content increased by 11.5% and 11.8%.
表2营养蛋白粉对大鼠股骨骨密度和骨钙、骨磷的影响(x±S)The impact of table 2 nutrient protein powder on rat femur bone mineral density and bone calcium, bone phosphorus (x ± S)
注:a与假性手术组相比P<0.01,b与去卵巢对照组相比P<0.05,c与去卵巢对照组相比P<0.01,Note: a P<0.01 compared with the sham operation group, b P<0.05 compared with the ovariectomized control group, c P<0.01 compared with the ovariectomized control group,
d与未强化大豆异黄酮组相比P<0.05,e与未强化大豆异黄酮组相比P<0.01dCompared with unfortified soybean isoflavone group, P<0.05, eCompared with unfortified soybean isoflavone group, P<0.01
6.营养蛋白粉对去卵巢大鼠血清生化指标的影响6. Effect of nutritional protein powder on serum biochemical indicators of ovariectomized rats
从表3中可以看出,与假性手术组相比去卵巢对照组大鼠血清AKP活性显著下降(P<0.05),下降12.90%。给予强化不同剂量大豆异黄酮的蛋白粉后,都有显著提高(P<0.01和P<0.05),与去卵巢对照组相比M-SI组和H-SI组分别提高25.00%和34.79%;与未强化大豆异黄酮组相比M-SI组和H-SI组分别提高10.86%和19.21%。It can be seen from Table 3 that compared with the sham operation group, the serum AKP activity of the rats in the ovariectomized control group decreased significantly (P<0.05), by 12.90%. After being given protein powder fortified with different doses of soybean isoflavones, all of them were significantly improved (P<0.01 and P<0.05), compared with the ovariectomized control group, the M-SI group and the H-SI group increased by 25.00% and 34.79% respectively; Compared with the non-fortified soybean isoflavone group, the M-SI group and H-SI group increased by 10.86% and 19.21%, respectively.
与假性手术组相比去卵巢对照组血清BGP含量显著升高(P<0.05),升高39.68%;给予中剂量的大豆异黄酮后血清BGP含量的升高得到了抑制(P<0.05),与去卵巢对照组相比下降了25.77%,与未强化大豆异黄酮组相比没有显著差异;给予高剂量的大豆异黄酮后血清BGP含量的升高也得到了抑制,但与去卵巢对照组和未强化大豆异黄酮组相比没有显著性差异。Compared with the sham operation group, the serum BGP content of the ovariectomized control group was significantly increased (P<0.05), an increase of 39.68%; the increase of serum BGP content was inhibited after the administration of medium doses of soybean isoflavones (P<0.05) , decreased by 25.77% compared with the ovariectomized control group, and there was no significant difference compared with the non-fortified soy isoflavone group; There was no significant difference between the group and the non-fortified soy isoflavone group.
表3营养蛋白粉对大鼠血清碱性磷酸酶和骨钙素的影响(x±S)Table 3 The effect of nutritional protein powder on rat serum alkaline phosphatase and osteocalcin (x ± S)
注:a与假性手术组相比P<0.05,b与去卵巢组相比P<0.05Note: a P<0.05 compared with the sham operation group, b P<0.05 compared with the ovariectomized group
c与去卵巢组相比P<0.01,d与未强化大豆异黄酮组相比P<0.05c Compared with the ovariectomized group, P<0.01, d Compared with the non-enriched soybean isoflavone group, P<0.05
AKP单位定义:100ml血清在37℃与基质作用15min产生1mg酚为一个金氏单位。Definition of AKP unit: 1 mg of phenol produced by 100 ml of serum reacting with the substrate at 37°C for 15 minutes is a King's unit.
7.结论:7. Conclusion:
本次实验给予强化大豆异黄酮的蛋白粉治疗去卵巢组大鼠3个月后,大鼠股骨骨密度(BMD)、骨钙和骨磷含量显著升高(p<0.01),表明大豆异黄酮能逆转因为雌激素缺乏而引起的骨丢失,起到防治骨质疏松的作用。血清中骨碱性磷酸酶活性(AKP)增加、骨钙素(BGP)含量降低,提示成骨细胞活性增加,骨转化速率下降,起到预防骨质疏松的作用。In this experiment, the protein powder fortified with soy isoflavones was given to treat ovariectomized rats for 3 months, and the femoral bone mineral density (BMD), bone calcium and bone phosphorus content of the rats increased significantly (p<0.01), indicating that soy isoflavones It can reverse the bone loss caused by estrogen deficiency and prevent osteoporosis. The increase of bone alkaline phosphatase activity (AKP) and the decrease of osteocalcin (BGP) content in serum indicate that the activity of osteoblasts increases and the rate of bone turnover decreases, which plays a role in preventing osteoporosis.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710150586XA CN101181069B (en) | 2007-11-30 | 2007-11-30 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710150586XA CN101181069B (en) | 2007-11-30 | 2007-11-30 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101181069A CN101181069A (en) | 2008-05-21 |
| CN101181069B true CN101181069B (en) | 2012-01-25 |
Family
ID=39446601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710150586XA Expired - Fee Related CN101181069B (en) | 2007-11-30 | 2007-11-30 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101181069B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2933617B1 (en) * | 2008-07-10 | 2010-09-17 | Alliospharma | COMPOSITIONS FOR PROMOTING THE DEVELOPMENT AND GROWTH OF A BENEFICIAL VAGINAL MICROFLORE |
| CN102599402B (en) * | 2011-01-25 | 2013-09-04 | 光明乳业股份有限公司 | Whey protein composition and preparation method thereof |
| CN103271166A (en) * | 2013-06-08 | 2013-09-04 | 山东省高唐蓝山集团总公司 | Soybean whey composite powder and preparation method thereof |
| CN104187244A (en) * | 2014-07-07 | 2014-12-10 | 山东省高唐蓝山集团总公司 | High-protein composition powder and preparation method thereof |
| CN104814445A (en) * | 2015-04-03 | 2015-08-05 | 梁德华 | Cardio-cerebrovascular disease preventing intensified protein powder and preparation method thereof |
| CN107249615B (en) * | 2015-04-07 | 2021-02-05 | 株式会社明治 | Hot flash inhibitor |
| CN105166937A (en) * | 2015-08-11 | 2015-12-23 | 曹峥峥 | Carya cathayensis protein powder |
| CN106666531A (en) * | 2016-12-28 | 2017-05-17 | 熙可食品(安徽)有限公司 | Cranberry can and preparation method thereof |
| CN110214955B (en) * | 2019-07-07 | 2024-02-02 | 广州正广生物科技有限公司 | Composition with function of nourishing ovaries and preparation method thereof |
| CN111357979A (en) * | 2019-12-26 | 2020-07-03 | 浙江欧谱生物科技有限公司 | Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof |
| CN113080469A (en) * | 2021-04-13 | 2021-07-09 | 广州金酮医疗科技有限公司 | Preparation method of protein component |
| CN119856777B (en) * | 2025-03-21 | 2026-01-30 | 四川大学华西第二医院 | A composition for improving perimenopausal symptoms |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1291442A (en) * | 2000-09-15 | 2001-04-18 | 卢挺 | Broad bean milk powder and its preparing process |
| CN100998368A (en) * | 2006-01-12 | 2007-07-18 | 天津科技大学 | Protein powder produced by fluidized bed spraying lecithinum granulation technique and preparing method thereof |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业(集团)股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
-
2007
- 2007-11-30 CN CN200710150586XA patent/CN101181069B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1291442A (en) * | 2000-09-15 | 2001-04-18 | 卢挺 | Broad bean milk powder and its preparing process |
| CN100998368A (en) * | 2006-01-12 | 2007-07-18 | 天津科技大学 | Protein powder produced by fluidized bed spraying lecithinum granulation technique and preparing method thereof |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业(集团)股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
Non-Patent Citations (2)
| Title |
|---|
| 张逢春等.大豆异黄酮抗骨质疏松症的实验研究及作用机制的探讨.《贵州医药》.2004,(第12期), * |
| 迟晓星等.大豆异黄酮对妇女更年期综合征及骨密度的作用研究.《中国骨质疏松杂志》.2005,(第03期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101181069A (en) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181069B (en) | Complex nutrition albumen powder for preventing women's osteosporosis after menopause | |
| Modan-Moses et al. | Peak bone mass in patients with phenylketonuria | |
| AU2011210683A1 (en) | Nutritional powders comprising spray dried HMB | |
| CN113841740A (en) | Sialic acid-containing infant formula milk powder and preparation method thereof | |
| CA2603518C (en) | Nutrient composition for promoting collagen production | |
| EP0934060A1 (en) | Dietary supplements | |
| CN108378374A (en) | Composition for preventing osteoporosis and promoting bone health | |
| CN1758906A (en) | Composition for improving obesity | |
| CN104146260B (en) | A kind of health food increasing bone density and preparation method thereof | |
| JPH0646797A (en) | Calcium absorption promoting composition containing soy milk | |
| Cho et al. | Effects of a safflower tea supplement on antioxidative status and bone markers in postmenopausal women | |
| EP3574770A1 (en) | Amino acid-containing composition | |
| JP2000191526A (en) | Composition for stimulating formation of bone and preventing and treating bone osteoporosis | |
| CN117678642A (en) | A composition that helps maintain healthy levels of blood lipids and preparation method thereof | |
| Lee et al. | Supplementation of Korean fermented soy paste doenjang reduces visceral fat in overweight subjects with mutant uncoupling protein-1 allele | |
| CN116585455A (en) | Nutritional package preparation for preventing senile osteoporosis and application thereof | |
| CN107802648A (en) | A kind of concocting method of the natural cod-liver oil of anti-curing osteoporosis | |
| Im Chung et al. | Enhancement of glucose and bone metabolism in ovariectomized rats fed with germinated pigmented rice with giant embryo (Oryza sativa L. cv. Keunnunjami) | |
| WO2008018139A1 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia | |
| Cho et al. | Effects of Artemisia princeps supplementation on bone metabolism in ovariectomized rats | |
| JP2004161619A (en) | Bone formation promoting composition | |
| AU2006347124B2 (en) | Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus Acacia | |
| Herawati et al. | Carica papaya leaf ethanol extract effect on milk volume, β-casein gene (Csn2) expression, β-casein levels, and milk total protein levels. | |
| CN120458257A (en) | A composition and its preparation method and application | |
| Thomas et al. | Flaxseed Derived Secoisolariciresinol diglucoside Enriched Fermented Milk Exhibits Antiosteopenic Effects in Ovariectomized Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120125 Termination date: 20131130 |


